Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HASPIN | Q8TF76 | 11/20 | 1.00 |
| ▸ | DYRK2 | Q92630 | 2/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 10/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15236175 | 0.86 | HASPIN (0.75) | HASPINDYRK2DYRK1A | |
| SCHEMBL16123595 | 0.85 | HASPIN (0.73) | HASPINDYRK2DYRK1A | |
| SCHEMBL30296700 | 0.84 | HASPIN (1.00) | HASPINDYRK2DYRK1A | |
| SCHEMBL30939880 | 0.84 | HASPIN (1.00) | HASPINDYRK2DYRK1A | |
| SCHEMBL15228128 | 0.84 | HASPIN (1.00) | HASPINDYRK2DYRK1A | |
| SCHEMBL30939966 | 0.84 | HASPIN (0.72) | HASPINDYRK2DYRK1A | |
| SCHEMBL16123625 | 0.84 | HASPIN (0.72) | HASPINDYRK2DYRK1A | |
| SCHEMBL16123609 | 0.84 | DYRK1A (0.72) | HASPINDYRK2DYRK1A | |
| SCHEMBL30939975 | 0.84 | DYRK1A (0.72) | HASPINDYRK2DYRK1A | |
| SCHEMBL15227864 | 0.84 | HASPIN (0.72) | HASPINDYRK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231360-A1 | Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases | THE BRIGHAM AND WOMEN S HOSPITAL, INC. (US) | 2013-09-05 | — | — | US | claimed |
| CN-113416187-B | Alkylamine harmine derivatives for promoting bone growth | 奥斯菲治疗有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-113416187-A | Alkylamine peganine derivatives for promoting bone growth | 奥斯特克有限公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-105120863-B | Alkylamine peganine derivatives for promoting bone growth | 奥斯特克有限公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20130231360-A1 | Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases | THE BRIGHAM AND WOMEN S HOSPITAL, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2011133795-A2 | BETA-CARBOLINES AS INHIBITORS OF HASPIN AND DYRK KINASES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231360-A1 | Beta-Carbolines as Inhibitors of Haspin and DYRK Kinases | HASPIN, HIPK1, HIPK2 | HASPIN 1/4885DYRK2 19/4885DYRK1A 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.